XPro1595

Evidence outlook · lead readout

NCT05318976 · Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders, Mild Cognitive Impairment

The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.

NCT05318976: This trial was properly randomized, quadruple-blinded, placebo-controlled, and enrolled a reasonably large cohort (207 patients) with a clinically meaningful cognitive endpoint (EMACC), which are all hallmarks of strong design. However, the posted primary-endpoint data show no statistically significant benefit was reported, and the raw numbers do not show the drug outperforming placebo, so the trial cannot be counted as positive evidence for the drug despite its otherwise solid design.